Vasgene Therapeutics, Inc.
Records under this name other than the patents Vasgene Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 10 of 10 · Back to Vasgene Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,533,026 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Term ended Ended no later than Sep 23, 2025 · USPTO record | Term ended | Ended no later than Sep 23, 2025 | USPTO record |
| US 7,862,816 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Jan 4, 2023 · USPTO record | Lapsed on the fee record | Ended Jan 4, 2023 | USPTO record |
| US 8,273,858 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Sep 25, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 25, 2020 | USPTO record |
| US 7,381,410 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Jun 3, 2020 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2020 | USPTO record |
| US 8,063,183 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Nov 22, 2019 · USPTO record | Lapsed on the fee record | Ended Nov 22, 2019 | USPTO record |
| US 7,977,463 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Jul 12, 2019 · USPTO record | Lapsed on the fee record | Ended Jul 12, 2019 | USPTO record |
| US 8,981,062 | Polypeptide compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Mar 17, 2019 · USPTO record | Lapsed on the fee record | Ended Mar 17, 2019 | USPTO record |
| US 7,906,116 | Methods for using and identifying modulators of Delta-like 4 Formerly held Lapsed on the fee record Ended Mar 15, 2019 · USPTO record | Lapsed on the fee record | Ended Mar 15, 2019 | USPTO record |
| US 8,975,377 | Cancer treatment using humanized antibodies that bind to EphB4 Lapsed on the fee record Ended Mar 10, 2019 · USPTO record | Lapsed on the fee record | Ended Mar 10, 2019 | USPTO record |
| US 7,585,967 | Nucleic acid compounds for inhibiting angiogenesis and tumor growth Lapsed on the fee record Ended Sep 8, 2013 · USPTO record | Lapsed on the fee record | Ended Sep 8, 2013 | USPTO record |